Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205300 | 1.00 | NR1H4 (0.34) | NR1H4MAPTTP53PDE4BKDM4E | |
| SCHEMBL2207549 | 0.91 | NR1H4 (0.32) | NR1H4MAPTTP53PDE4B | |
| SCHEMBL2207545 | 0.91 | NR1H4 (0.32) | NR1H4MAPTTP53PDE4B | |
| SCHEMBL2207550 | 0.91 | NR1H4 (0.32) | NR1H4MAPTTP53PDE4B | |
| SCHEMBL2205359 | 0.87 | PDE4B (0.32) | MAPTTP53PDE4B | |
| SCHEMBL2205352 | 0.87 | PDE4B (0.32) | MAPTTP53PDE4B | |
| SCHEMBL2207542 | 0.84 | — | — | |
| SCHEMBL2205741 | 0.81 | KCNH2 (0.42) | — | |
| SCHEMBL2205744 | 0.81 | KCNH2 (0.42) | — | |
| SCHEMBL4709824 | 0.81 | MAPT (0.35) | NR1H4MAPTTP53KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981886-B2 | Antibiotics derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-07-19 | — | — | US | disclosed |
| EP-1888574-B1 | NEW ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080280888-A1 | Antibiotics Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280888-A1 | Antibiotics Derivatives | NR4A1, NR2C2, NR4A3 | NR1H4 5/4885MAPT 4688/4885TP53 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.